Munich-based medical technology startup Noxon has completed a seed financing round worth millions. The round is led by High-Tech Gründerfonds (HTGF), with Bayern Kapital, Auxxo, and another institutional investor also participating. Noxon intends to use the fresh capital to further develop its non-invasive muscle-computer interface technology, clinically validate it, and obtain regulatory approval. The goal is to transition from research to clinical application and prepare for market entry.
Strong and healthy muscles are a key prerequisite for mobility, independence, and healthy aging. Nevertheless, muscle activity in everyday life remains largely invisible. While numerous other bodily functions can be precisely measured and analyzed, muscle signals are usually only recorded selectively and under clinical conditions.
More than a billion people worldwide are affected by muscle diseases. Whether in Parkinson's disease, scoliosis, or rehabilitation after an accident or stroke, continuous data from everyday life is often lacking. As a result, it remains unclear whether muscles are working at the right time, with the appropriate intensity, and in coordination with other muscle groups. Until now, therapies have only been able to be individualized and adapted for the long term to a limited extent.
Noxon is addressing this issue with a novel, non-invasive muscle computer interface. The technology discreetly integrates sensors into clothing and measures muscle signals directly on the body. These signals are translated into analyzable data and enable continuous recording of muscle activity in everyday life. For the first time, muscle activity can be systematically monitored outside of clinics and used specifically for therapy, training, and prevention.
The platform combines continuous measurement and targeted stimulation of muscles. This allows treatments to be personalized and dynamically adjusted throughout the entire course of therapy—not just during individual sessions in rehabilitation centers or hospitals. The goal is to make muscle therapy data-driven, individualized, and suitable for everyday use.
Noxon was founded in 2022 as a spin-off of three renowned universities, including the Karlsruhe Institute of Technology, the Technical University of Munich, and the Munich University of Applied Sciences. The founding team combines expertise in neuroscience, medical technology, hardware and software development, AI-based signal processing, and clinical translation.
With seed financing, the company is now laying the foundation for the next steps in its development. The focus is on clinical validation of the technology, regulatory approval of the platform, and the expansion of standardized therapy modules as a prerequisite for broad application.
The market for rehabilitation and neurotechnology is increasingly moving toward digital, outpatient, and personalized solutions. Driven by demographic change and a rising number of chronic diseases, there is a growing need for therapies that function independently of inpatient structures. Noxon is positioning itself in this environment with a scalable wearable platform that combines continuous muscle measurement and stimulation, opening up new perspectives for large groups of patients with neurological or musculoskeletal disorders. The company sees additional potential in related areas such as prevention and performance optimization.